Last reviewed · How we verify
Minocycline plus tretinoin
Minocycline plus tretinoin is a Tetracycline antibiotic + retinoid combination Small molecule drug developed by Derm Research @ 888 Inc.. It is currently FDA-approved for Acne vulgaris. Also known as: Minocin, Tretinoin.
Minocycline is a tetracycline antibiotic with anti-inflammatory properties, while tretinoin is a retinoid that promotes skin cell turnover and reduces sebum production; together they target bacterial infection and inflammation in acne.
Minocycline is a tetracycline antibiotic with anti-inflammatory properties, while tretinoin is a retinoid that promotes skin cell turnover and reduces sebum production; together they target bacterial infection and normalize keratinization in acne. Used for Acne vulgaris.
At a glance
| Generic name | Minocycline plus tretinoin |
|---|---|
| Also known as | Minocin, Tretinoin |
| Sponsor | Derm Research @ 888 Inc. |
| Drug class | Tetracycline antibiotic + retinoid combination |
| Target | Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Minocycline inhibits bacterial protein synthesis and has immunomodulatory effects that reduce inflammatory cytokines and neutrophil activity. Tretinoin normalizes keratinization, increases cell turnover, and reduces comedone formation. The combination addresses multiple pathogenic factors in acne: bacterial colonization, inflammation, and abnormal follicular keratinization.
Approved indications
- Acne vulgaris
Common side effects
- Photosensitivity
- Skin irritation and peeling (tretinoin)
- Dizziness or vertigo (minocycline)
- Nausea
- Vaginal yeast infection
Key clinical trials
- A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris (PHASE4)
- Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19 (PHASE2)
- Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin (PHASE4)
- Combination Treatment for Moderate to Severe Acne (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minocycline plus tretinoin CI brief — competitive landscape report
- Minocycline plus tretinoin updates RSS · CI watch RSS
- Derm Research @ 888 Inc. portfolio CI
Frequently asked questions about Minocycline plus tretinoin
What is Minocycline plus tretinoin?
How does Minocycline plus tretinoin work?
What is Minocycline plus tretinoin used for?
Who makes Minocycline plus tretinoin?
Is Minocycline plus tretinoin also known as anything else?
What drug class is Minocycline plus tretinoin in?
What development phase is Minocycline plus tretinoin in?
What are the side effects of Minocycline plus tretinoin?
What does Minocycline plus tretinoin target?
Related
- Drug class: All Tetracycline antibiotic + retinoid combination drugs
- Target: All drugs targeting Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin)
- Manufacturer: Derm Research @ 888 Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Also known as: Minocin, Tretinoin
- Compare: Minocycline plus tretinoin vs similar drugs
- Pricing: Minocycline plus tretinoin cost, discount & access